{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T20:53:44Z","timestamp":1786136024419,"version":"build-2736575974"},"reference-count":36,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T00:00:00Z","timestamp":1747872000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004330","name":"GSK plc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.clml.2025.05.019","type":"journal-article","created":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T05:14:58Z","timestamp":1747718098000},"page":"e779-e787.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Practical Guidance on the Clinical Management of Belantamab Mafodotin for Patients With Relapsed\/Refractory Multiple Myeloma: Recommendations From the Middle East and North Africa Expert Panel"],"prefix":"10.1016","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1797-8657","authenticated-orcid":false,"given":"Meral","family":"Beksa\u00e7","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1355-7284","authenticated-orcid":false,"given":"Esra","family":"Sahli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9060-6492","authenticated-orcid":false,"given":"Ahmed","family":"Rabea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8646-1673","authenticated-orcid":false,"given":"Guray","family":"Saydam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7195-1845","authenticated-orcid":false,"given":"Anil","family":"Tombak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4669-0233","authenticated-orcid":false,"given":"Ahmad","family":"Alhuraiji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7973-8160","authenticated-orcid":false,"given":"Enas Yahya","family":"Mutahar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7243-0224","authenticated-orcid":false,"given":"Mohamed","family":"Hosny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2142-2654","authenticated-orcid":false,"given":"Ayman","family":"Alhejazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mervat","family":"Mattar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5994-2735","authenticated-orcid":false,"given":"Mehmet Sinan","family":"Dal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7368-3998","authenticated-orcid":false,"given":"Mahmoud","family":"Marashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2494-0131","authenticated-orcid":false,"given":"Melis","family":"Palamar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.clml.2025.05.019_bib0001","first-page":"209","article-title":"Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"10.1016\/j.clml.2025.05.019_bib0002","doi-asserted-by":"crossref","first-page":"67","DOI":"10.46989\/001c.92555","article-title":"Epidemiology, treatment trends, and outcomes of multiple myeloma in the Middle East and Africa: a systematic review","volume":"6","author":"Mattar","year":"2024","journal-title":"Clin Hematol Int"},{"issue":"4","key":"10.1016\/j.clml.2025.05.019_bib0003","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s44228-022-00017-3","article-title":"Management of multiple myeloma in the Middle East: unmet needs, challenges and perspective","volume":"4","author":"Ibrahim","year":"2022","journal-title":"Clin Hematol Int"},{"issue":"4","key":"10.1016\/j.clml.2025.05.019_bib0004","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41408-019-0200-1","article-title":"Treatment of patients with multiple myeloma progressing on frontline-therapy with lenalidomide","volume":"9","author":"Moreau","year":"2019","journal-title":"Blood Cancer J"},{"issue":"1","key":"10.1016\/j.clml.2025.05.019_bib0005","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1200\/JOP.19.00244","article-title":"Current treatment strategies for multiple myeloma","volume":"16","author":"Branagan","year":"2020","journal-title":"JCO Oncol Pract"},{"issue":"1","key":"10.1016\/j.clml.2025.05.019_bib0006","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/s41408-023-00804-y","article-title":"Clinical evidence for immune-based strategies in early-line multiple myeloma: current challenges in decision-making for subsequent therapy","volume":"13","author":"Raje","year":"2023","journal-title":"Blood Cancer J"},{"issue":"3","key":"10.1016\/j.clml.2025.05.019_bib0007","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.annonc.2020.11.014","article-title":"Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up\u2020","volume":"32","author":"Dimopoulos","year":"2021","journal-title":"Ann Oncol"},{"issue":"Suppl","key":"10.1016\/j.clml.2025.05.019_bib0008","article-title":"Updates to the management of multiple myeloma","volume":"22","author":"Callander","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.clml.2025.05.019_bib0009","doi-asserted-by":"crossref","first-page":"7023","DOI":"10.1182\/blood-2024-206259","article-title":"Outcomes of patients with newly diagnosed myeloma both transplant eligible and ineligible in North Africa: a Usmirc- Morocco\/Tunisia collaboration","volume":"144","author":"Ben Sayed","year":"2024","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.clml.2025.05.019_bib0010","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1182\/blood-2013-10-535088","article-title":"Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma","volume":"123","author":"Tai","year":"2014","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.clml.2025.05.019_bib0011","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1007\/s40123-020-00280-8","article-title":"Corneal epithelial findings in patients with multiple myeloma treated with antibody-drug conjugate belantamab mafodotin in the pivotal, randomized, DREAMM-2 study","volume":"9","author":"Farooq","year":"2020","journal-title":"Ophthalmol Ther"},{"issue":"10","key":"10.1016\/j.clml.2025.05.019_bib0012","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1089\/jop.2015.0064","article-title":"Ocular adverse events associated with antibody-drug conjugates in human clinical trials","volume":"31","author":"Eaton","year":"2015","journal-title":"J Ocul Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.clml.2025.05.019_bib0013","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s10637-017-0520-6","article-title":"Clinical toxicity of antibody drug conjugates: a meta-analysis of payloads","volume":"36","author":"Masters","year":"2018","journal-title":"Invest New Drugs"},{"issue":"5","key":"10.1016\/j.clml.2025.05.019_bib0014","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJMoa2405090","article-title":"Belantamab mafodotin, bortezomib, and dexamethasone for multiple myeloma","volume":"391","author":"Hungria","year":"2024","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.clml.2025.05.019_bib0015","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1056\/NEJMoa2403407","article-title":"Belantamab mafodotin, pomalidomide, and dexamethasone in multiple myeloma","volume":"391","author":"Dimopoulos","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2025.05.019_bib0016","unstructured":"European Medicines Agency. EMA recommends non-renewal of authorisation of multiple myeloma medicine Blenrep. Accessed March, 2025. https:\/\/www.ema.europa.eu\/en\/news\/ema-recommends-non-renewal-authorisation-multiple-myeloma-medicine-blenrep. 2023."},{"key":"10.1016\/j.clml.2025.05.019_bib0017","unstructured":"Food and Drug Administration. FDA granted accelerated approval to belantamab mafodotin-blmf for multiple myeloma. Accessed March, 2025. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-granted-accelerated-approval-belantamab-mafodotin-blmf-multiple-myeloma. 2023."},{"issue":"10","key":"10.1016\/j.clml.2025.05.019_bib0018","doi-asserted-by":"crossref","first-page":"e801","DOI":"10.1016\/S2352-3026(23)00243-0","article-title":"Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a phase 3, open-label, randomised study","volume":"10","author":"Dimopoulos","year":"2023","journal-title":"Lancet Haematol"},{"issue":"5","key":"10.1016\/j.clml.2025.05.019_bib0019","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/s41408-021-00494-4","article-title":"Management of belantamab mafodotin-associated corneal events in patients with relapsed or refractory multiple myeloma (RRMM)","volume":"11","author":"Lonial","year":"2021","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2025.05.019_bib0020","doi-asserted-by":"crossref","unstructured":"Hungria V, Robak P, Hus M, et al. International Myeloma Society (IMS) Annual Meeting; 25-28 September 2024. P-396: characterization and management of ocular events in patients treated with belantamab mafodotin plus bortezomib and dexamethasone in the DREAMM-7 study.","DOI":"10.1016\/S2152-2650(24)02298-5"},{"key":"10.1016\/j.clml.2025.05.019_bib0021","doi-asserted-by":"crossref","unstructured":"Quach H, Dimopoulos MA, Beksac M, et al. International Myeloma Society (IMS) Annual Meeting; 25-28 September 2024. P-413: characterization and management of ocular events in patients treated with belantamab mafodotin plus pomalidomide and dexamethasone in the DREAMM-8 study.","DOI":"10.1016\/S2152-2650(24)02315-2"},{"issue":"7","key":"10.1016\/j.clml.2025.05.019_bib0022","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1097\/00003226-200310000-00008","article-title":"Grading of corneal and conjunctival staining in the context of other dry eye tests","volume":"22","author":"Bron","year":"2003","journal-title":"Cornea"},{"key":"10.1016\/j.clml.2025.05.019_bib0023","unstructured":"Feroze KB, Zeppieri M, Khazaeni L. Steroid-induced glaucoma. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK430903."},{"issue":"2","key":"10.1016\/j.clml.2025.05.019_bib0024","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1080\/10428194.2022.2136950","article-title":"From mechanism to resistance - changes in the use of dexamethasone in the treatment of multiple myeloma","volume":"64","author":"Rosenberg","year":"2023","journal-title":"Leuk Lymphoma"},{"issue":"Suppl 1","key":"10.1016\/j.clml.2025.05.019_bib0025","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1182\/blood-2024-198669","article-title":"Phase I study of belantamab mafodotin in combination with standard of care in transplant-ineligible newly diagnosed multiple myeloma: DREAMM-9 updated interim analysis","volume":"144","author":"Usmani","year":"2024","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clml.2025.05.019_bib0026","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jtos.2017.10.005","article-title":"Randomized double-masked trial of eyelid cleansing treatments for blepharitis","volume":"16","author":"Sung","year":"2018","journal-title":"Ocul Surf"},{"issue":"1","key":"10.1016\/j.clml.2025.05.019_bib0027","article-title":"Improvement of amniotic membrane method for the treatment of corneal perforation","volume":"2016","author":"Fan","year":"2016","journal-title":"BioMed Res Int"},{"issue":"10","key":"10.1016\/j.clml.2025.05.019_bib0028","article-title":"Endophthalmitis after cataract surgery: a postoperative complication","volume":"14","author":"Wadbudhe","year":"2022","journal-title":"Cureus"},{"issue":"6","key":"10.1016\/j.clml.2025.05.019_bib0029","doi-asserted-by":"crossref","first-page":"467","DOI":"10.3341\/kjo.2021.0068","article-title":"Effects of Glaucoma medication on dry eye syndrome and quality of life in patients with Glaucoma","volume":"35","author":"Maeng","year":"2021","journal-title":"Korean J Ophthalmol"},{"issue":"2","key":"10.1016\/j.clml.2025.05.019_bib0030","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1097\/ICO.0000000000000038","article-title":"A review of quality of life measures in dry eye questionnaires","volume":"33","author":"Grubbs","year":"2014","journal-title":"Cornea"},{"issue":"4","key":"10.1016\/j.clml.2025.05.019_bib0031","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.joco.2018.05.002","article-title":"Association between dry eye symptoms and signs","volume":"30","author":"Kyei","year":"2018","journal-title":"J Curr Ophthalmol"},{"issue":"3","key":"10.1016\/j.clml.2025.05.019_bib0032","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1002\/ajh.27219","volume":"99","author":"Gavriatopoulou","year":"2024","journal-title":"Am J Hematol"},{"issue":"4","key":"10.1016\/j.clml.2025.05.019_bib0033","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.4103\/IJO.IJO_2789_22","article-title":"Omega-3 fatty acids supplements for dry eye - are they effective or ineffective?","volume":"71","author":"Bhargava","year":"2023","journal-title":"Indian J Ophthalmol"},{"issue":"10","key":"10.1016\/j.clml.2025.05.019_bib0034","first-page":"1487","article-title":"Alcohol consumption and dry eye syndrome: a meta-analysis","volume":"9","author":"You","year":"2016","journal-title":"Int J Ophthalmol"},{"issue":"10","key":"10.1016\/j.clml.2025.05.019_bib0035","first-page":"1480","article-title":"Smoking and the risk of dry eye: a meta-analysis","volume":"9","author":"Xu","year":"2016","journal-title":"Int J Ophthalmol"},{"key":"10.1016\/j.clml.2025.05.019_bib0036","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.2147\/NSS.S378751","article-title":"The Association between Dry eye and Sleep disorders: the evidence and possible mechanisms","volume":"14","author":"Li","year":"2022","journal-title":"Nat Sci Sleep"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025001843?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025001843?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T20:04:24Z","timestamp":1786133064000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265025001843"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":36,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S2152265025001843"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2025.05.019","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Practical Guidance on the Clinical Management of Belantamab Mafodotin for Patients With Relapsed\/Refractory Multiple Myeloma: Recommendations From the Middle East and North Africa Expert Panel","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2025.05.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}